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Abstract
Assessment of ethical aspects and authorization by ethics committees have become a major constraint for health
research including human subjects. Ethical reference values often are extrapolated from clinical settings, where emphasis
lies on decisional autonomy and protection of individual's privacy. The question rises if this set of values used in clinical
research can be considered as relevant references for HBM research, which is at the basis of public health surveillance.
Current and future research activities using human biomarkers are facing new challenges and expectancies on sensitive
socio-ethical issues. Reflection is needed on the necessity to balance individual rights against public interest. In addition,
many HBM research programs require international collaboration. Domestic legislation is not always easily applicable in
international projects. Also, there seem to be considerable inconsistencies in ethical assessments of similar research
activities between different countries and even within one country. All this is causing delay and putting the researcher in
situations in which it is unclear how to act in accordance with necessary legal requirements. Therefore, analysis of ethical
practices and their consequences for HBM research is needed.
This analysis will be performed by a bottom-up approach, based on a methodology for comparative analysis of
determinants in ethical reasoning, allowing taking into account different social, cultural, political and historical traditions,
in view of safeguarding common EU values. Based on information collected in real life complexity, paradigm cases and
virtual case scenarios will be developed and discussed with relevant stakeholders to openly discuss possible obstacles
and to identify options for improvement in regulation. The material collected will allow developing an ethical framework
which may constitute the basis for a more harmonized and consistent socio-ethical and legal approach. This will not only
increase the possibilities for comparison between data generated but may also allow for more equality in the protection
of the rights of European citizens and establish trustful relationships between science and society, based on firmly rooted
ethical values within the EU legislative framework.
These considerations outline part of the research on legal, socio-ethical and communication aspects of HBM within the
scope of ECNIS (NoE) and NewGeneris (IP).
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Background
Human biomonitoring (HBM) is a useful tool to assess
human exposures to environmental agents and their
health effects, based on sampling and analysis of an indi-
vidual's tissue and fluid. Biomarkers indicate steps in a
series of events leading to diseases that may result from
exposure to (toxic) pollutants or harmful agents. Because
many significant diseases develop over longer periods of
time, methods for detecting early markers that can predict
risk are important for disease prevention.
Current and future research activities using human
biomarkers are facing new challenges and expectancies on
sensitive socio-ethical issues, especially in the environ-
mental public health context where activities should lead
to policy, preventive actions and raising awareness at pop-
ulation level. Hence the notion of public interest comes
more and more to the forefront, leading to substantial dif-
ferences as compared to clinical settings, in terms of risk-
benefit balance and consequences for the individual and
for the entire population and in terms of required com-
munication practices. Reflection is needed on the ways to
balance individual decision-making as an expression of
individual rights against the public interest. HBM studies
often require a maximal participation of given popula-
tions in order to provide reliable knowledge, which may
then be beneficial for protecting people through preven-
tive action. The appropriateness of the current legal and
ethical framework, mainly issuing from and applicable to
clinical medicine, and therefore representing a strongly
individual-oriented approach, should therefore be
assessed. At the same time, domestic legislation is not
always easily applicable in international collaborative
research projects, causing delay and putting the researcher
in situations in which it is unclear how to act in accord-
ance with all necessary legal requirements on ethical
aspects of research. As a consequence, scientific opportu-
nities may be missed and important developments of
which many individuals will benefit, hampered.
The key questions at stake are how research subjects
involved in HBM research can be adequately and equally
protected throughout the whole of Europe whilst at the
same time scientific research in the field of environmental
health developing human biomarkers and also surveil-
lance studies and practices using HBM with a view to pro-
tect people, are not simply being restricted nor prevented
for the wrong reasons. Documenting and analyzing cur-
rent practices is a method to allow identification of both
bottlenecks and not allowable shortcuts in this process.
These practices can be represented and discussed as such
or translated into virtual cases. The latter may facilitate
open discussions.
Indeed, whilst in general there is a willingness to be in
compliance with what can reasonably be expected from
ethically correct conducted research, researchers are faced
with a labyrinth of rules and guidelines, often open for
interpretation, which leaves them worried about the fact
that the legitimacy of the research which is ongoing might
be challenged [1]. In what follows, specific ethical chal-
lenges in HBM studies will be highlighted trough such
cases. They relate to decision-making processes, including
informed consent, to communication aspects, and to eth-
ical assessment and approval procedures. The methodol-
ogy of the ethical research within ECNIS http://
www.ecnis.org and NewGeneris http://www.new
generis.org projects and the search for intermediate solu-
tions to practical problems that researchers within the
group are faced with will be explained briefly.
Current practices
The World Wildlife Fund (WWF) has organised several
HBM surveys in the past few years testing people across
the whole of Europe http://www.panda.org/about_wwf/
what_we_do/policy/toxics/problems/
whats_in_your_blood/index.cfm. The goal of these sur-
veys was not to prove a scientific hypothesis, but to raise
awareness of the general public about the extent of chem-
ical pollution in Europe and to show how essential a
strong European chemical regulation is. The results have
shown that persons tested are 'contaminated' with a cock-
tail of persistent, bio-accumulative and toxic man-made
chemicals. Although the study was conducted in full
respect of the rights of each participant, questions were
brought up about the exact procedures to follow, on
which it seemed difficult to get consistent answers.
According to the protocol of the Convention on Human
Rights and Biomedicine (ref [2], article 7), every
"research" project has to be submitted to an independent
research ethics committee and approval of an ethics com-
mittee has to be required before the start of the project. In
the case of WWF the question was raised weather such a
campaign had to be considered a "research" project or
not, since its purpose is not primarily to produce knowl-
edge but to raise awareness. Furthermore, only very few
samples were collected in a large number of countries (13
families from 12 EU countries) http://assets.panda.org/
downloads/generationsx.pdf and it was unclear whether
ethical approvals were required in each country.
Other difficulties in the correct implementation of the
rules and guidelines relate to the secondary use of samples
and/or personal data. According to the EU Privacy legisla-
tion [3], data should not be processed further in a way
incompatible with the specific purposes for which the
data have been collected. However, further processing of
personal data (the so called secondary use of data) is gen-
erally not considered incompatible with the purposes forEnvironmental Health 2008, 7(Suppl 1):S7 http://www.ehjournal.net/content/7/S1/S7
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which the data have previously been collected provided
that Member States furnish suitable safeguards (Article 13
of the Directive 95/46/EC). If a new purpose is found
incompatible, the research proposal is considered as a
new project and consequently a new individual informed
consent must be requested. There may be exceptions: if
the provision of information to the research subject
proves impossible or would involve disproportionate
efforts, a new consent is not necessary on the condition
that this has been explained to the national privacy
authority where the notification is done. Divergent inter-
pretations on the "compatibility of a purpose" and on
what is "impossible or disproportionate effort" reflect
uncertainties about the best interpretation of the Directive
and may cause confusion. Can, for instance, in the devel-
opment of new and validating DNA repair phenotypes for
which an informed consent was previously obtained for
genotyping, the samples be reused without obtaining new
individual consent for phenotyping?
The above examples illustrate the need to clarify and
maybe even to facilitate formal legal aspects and ethical
constraints of HBM practices. This need is not only
present for academic research, but also in other activities
using HBM, such as surveillance programs and raising
awareness campaigns.
Specific for many studies in environmental health is the
direct involvement of various stakeholders from the start
on: industry, NGO's, politicians and authorities. A Euro-
barometer survey published by the European Commis-
sion showed that medical and health organizations such
as 'The Red Cross' and 'Médecins sans frontières' are the
most trusted sources of health information across the EU
(trusted by 84%). Consumer organizations are the second
most trusted source (67%), closely followed by schools
and universities (65.5%) and environmental organiza-
tions (63%). The media was trusted by 39% of people sur-
veyed, governments by 23% while business and political
parties had the lowest trust rating when it comes to health
information (16% and 11% respectively) http://
ec.europa.eu/health/ph_information/indicators/
pub_indic_data_en.htm.
However, in HBM studies the latter are playing a major
role besides the health professionals. If for instance an
increase in lung cancer risk has been attributed to histori-
cal cadmium pollution due to industrial activities in a cer-
tain region, the population concerned will be deeply
alarmed about the impact of the pollution on their health.
They will look for specific actions from the policy makers
and the industry at the origin of the pollution and for
information on individual health risk. According to the
"polluter pays" principle, the industry at the origin of the
pollution should contribute to sanitation of the contami-
nated soil and to evaluation of the effects of their interven-
tions. A HBM study in the affected area may be one of the
tools. However, in this kind of situation, how will the
(affected) population perceive a (financial) involvement
of industry in the HBM study? Will the people have trust
in a transparent and fair interpretation and communica-
tion of data?
In many cases, communication of results to the research
subjects is a difficult endeavor, as both the right to know
and the right not to know need to be respected. The infor-
mation provided should be correct and understandable
and avoid raising unnecessary alarm, although interpreta-
tion of the data collected may be difficult and not straight-
forward, as may be illustrated by the following example.
Under the auspices of the United Nations Environment
Program (UNEP), at the ratification of the Stockholm
Convention on persistent organic pollutants (POP's) in
2004, it was decided to perform a reduction of the twelve
most present POP's in the environment. To test the effi-
ciency of the policy agreements, the World Health Organ-
ization (WHO) coordinates currently the fourth survey
round on pollutants in breast milk throughout the world
in order to measure the levels of POP's, such as PCBs,
PCDDs and PCDFs http://www.who.int/foodsafety/
chem/POPprotocol.pdf. The results demonstrate that
breast milk contains many pollutants. It is know that dur-
ing breastfeeding, a transfer of the body burden from
mother to child takes place. Communication of such
results to the mothers risks to raise panic and induce anx-
iety and even guilt feelings. On the other hand, it is scien-
tifically clear that breast-feeding has many advantages to
babies and mothers with respect to protection against dis-
eases and to the comfort and physical closeness it entails.
The foremost question to pose is how not to overestimate
the risks or downplay the benefits of breast-feeding to the
mothers? Three possibilities in communication of results
can be considered. The first one would be never to com-
municate on individual level as the general rule. Commu-
nication of results will then only include information at
the collective level and focus for example in the specific
situation of the downward trend in the concentration of
POP's over time. However research participants have a
right to know the data that have been processed, as guar-
anteed by the EU Directive 95/46/EC (article 12 of [3]).
Therefore communication of individual results should be
performed either as a general rule, unless specified other-
wise by the study participant during the informed consent
procedure, either on request only.
The right to know or not to know may also entail close rel-
atives. Consider the case where employees in a factory are
long-term exposed to pollutants that might impact their
health status and the health status of their offspring. SinceEnvironmental Health 2008, 7(Suppl 1):S7 http://www.ehjournal.net/content/7/S1/S7
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there exists a growing trend in society to lift conflicts of
various natures at judicial level, it would not be unrealistic
to be confronted with the right to know effected by the
children of exposed employees who require compensa-
tion for possible damage on their health and lives.
As stated above, the protocol of the Convention on
Human Rights and Biomedicine indicates that biomedical
research can only be conducted with the approval from a
research ethics committee. The lack of harmonization of
ethics committee processes across Europe, the need for a
simplified research governance framework, and the
"inconsistency" as a result of the inherent variability in
moral judgment were reported [4].
Also the composition of ethics committees across Europe
varies [5]. Risk and benefit analysis in environmental
health studies may require a specific competence that is
not always available in REC's. An ethics committee with
roots solely in the clinical world may have a very different
appreciation than an ethics committee which has more
expertise in public health matters. For instance the use of
a tumor marker (TM) to screen for cancer needs a different
judgment then the use of the same TM to assess exposure
to pollutants. A marker might be acceptable in a clinical
research study in view of identifying early markers of dis-
ease. Using the same TM to assess impact of exposure at
population level however is a different matter. Although
in the latter case it is not the objective to identify at risk
persons, results will become available that give indica-
tions for an elevated risk at individual level. This is espe-
cially difficult if the TM is not highly predictive, implying
that, as a consequence of large scale testing, a considerable
amount of false positive persons will be revealed. These
persons may go for diagnostic procedures that may cause
unnecessary side effects, not to forget that the cancer treat-
ment itself may cause a lot of side effects, even if the test
may detect insignificant tumors that would never become
clinically life threatening. From a medical point of view, it
is not yet known if the test actually saves lives and if the
benefits of screening outweigh the risks of follow up diag-
nostic tests (e.g. biopsy) and cancer treatments. With
respect to its relevance for environmental exposure, it is
not generally accepted nor validated that a specific causal
linkage exists. Being given this information, the issue is
whether the use of this TM test in environment and health
survey settings would be acceptable? If it is acceptable,
which are the conditions? Who decides on the use and on
the acceptability of using the TM test? Should the decision
be taken by scientists and/or by policy makers and/or by
a local ethics committee? A clinically oriented ethics com-
mittee which is not familiar with the reasoning of public
health practices may content itself with approving the
project insisting mainly on the free informed consent.
At recruitment phase an informed consent procedure is a
necessary condition to involve healthy volunteers in HBM
research in all EU Member States. However, procedures
and contents of the process vary significantly across EU
Member States. Particularly difficult is the involvement of
children. A variety of large mother-child cohorts are set or
being set up in many European countries http://
www.birthcohorts.net/About.asp. Increasing awareness of
long-term health effects from early life towards childhood
and adolescent age is the basis of this approach. Knowl-
edge on the genotoxicity of contaminants in children is a
necessary scientific basis for possible further European
regulatory activities. Who will decide on the participation
of children in such studies? The acceptability of risks that
the research may impose on the children and the respect
for their autonomy are considered relevant ethical consid-
erations. However, questions remain on the age that chil-
dren are able to make decisions consciously and
independently [5]. In some European Member States col-
lection of personal data and/or samples of children
related to medical and health care purposes are kept under
auspices of the parents until the children reach the age of
eighteen. Curiously, at the same time, in the case where
databases keep data and/or samples of young children
related to criminal purposes, the children have the author-
ity to decide for themselves from the age of thirteen. How
come in one case children are assumed to be able to make
autonomous decisions and in another case not? Biologi-
cal age is certainly not the only criterion to decide upon
http://www.cesagen.lancs.ac.uk/research/related/ines.htm
[6].
Another challenge emerges in many EU Member States:
the inclusion of many ethnic and cultural minorities in
research projects. In research on gene-environment inter-
actions, there is a growing interest to integrate different
ethnic groups, since they represent different dietary habits
and possibly different exposures. Imagine that mothers
are being recruited to participate in a large mother-child
cohort. Different ethnicities or religious backgrounds
might stand for considerable differences in the extent to
which the mother makes her own decisions or otherwise
the father decides for her, whether or not she may partici-
pate in the study cohort. In an increasingly pluralistic soci-
ety, how should culture and identity be respected but at
the same time the autonomy and dignity of the mother
guaranteed without hampering the dignity of the father
[7]?
Ethics, an obstacle for research?
In HBM research ethics often comes across at first in the
legal obligation to comply with all national and EU legis-
lation, irrespective of the 'thicker' meaning of conducting
science in an ethical way. For instance, the legal require-
ment to apply to local ethics committees for approvalEnvironmental Health 2008, 7(Suppl 1):S7 http://www.ehjournal.net/content/7/S1/S7
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before the start of research may be perceived as a bureau-
cratic "nuisance" because it stands for a bunch of time
consuming paper work that might cause delay in research.
Moreover, in the existing ethical framework including
national, European and international regulations, inter-
national conventions and declarations, as well as guide-
lines and opinions (i.a. EU Directive 95/46/EC, Council
of Europe's Convention on Human Rights and Biomedi-
cine), researchers may be put in situations in which it is
unclear how to act in accordance with all necessary legal
requirements of ethical aspects of research. In transna-
tional research projects, which are key tools in further
investigations of the health impact caused by environ-
mental factors on a large scale, and in which transfer of
sensitive personal data and/or biological samples from
one Member State to another is a common practice, the
labyrinth of rules and guidelines becomes an even larger
clew. As a consequence, significant scientific develop-
ments may be missed whilst juggling with ethical con-
cepts and rules, which in the worst of cases may even
overlook the main objective. Alternatively, ethical
approval might be shortcut.
Decision making processes
Analysis of decision making processes are at the core of
the below presented approach and in line with the meth-
odology for comparative analysis of the determinants of
ethical reasoning. Any situation calls for the one foremost
question to be analyzed: who decides upon what for
whom, why, how, on which grounds and with which con-
sequences for whom? Decision making processes are to be
considered at several levels. Who initiates the study? Who
decides on the design of a research project? Who decides
on the use of a certain biomarker? Why does a healthy vol-
unteer decide to participate in it?
In environmental health research, it may be unclear
whether the concept of autonomy, as implemented via
informed consent, is always the most appropriate or the
necessary way for decision making in a research domain
where societal interests often directly surpass the individ-
ual interest. An additional question in that respect is
whether, and to what extent-also in clinical situations- an
informed consent can be considered free and authentic,
and based on a correct understanding of the issue at stake.
Some of the above examples illustrate the complexity of
finding the appropriate way to implement the informed
consent principle and how it should apply.
It is obvious that a signed consent on paper alone does
not adequately protect the rights and dignity of every par-
ticipating individual. By applying ethics in a procedural
manner, the real meaning of informed consent – to make
well informed and autonomous decision – may be jeop-
ardized.
Anyhow, also when individual informed consent would
not be the key regulatory principle in some HBM research
or surveillance practices, it is important that the person
should be fully informed on what the research or practice
is about, and on the reasons why no consent is asked for.
Ethics committees
Often the ethics committee has a unique strong position
in the decision making process on the acceptability of a
project. However, the composition of members of local
ethics committees is often bound for decision making in
clinical situations.
Questions related to the role of local ethics committees
are relevant since the incidence of ad hoc and very local
debates indicate that there is little consistency, which may
even lead to a 'shopping' phenomenon: studies will be
undertaken where the 'resistance' is low.
A need for adapted communication strategies?
As refered to above, according to the EU Privacy Directive
every research subject has the right to know about all per-
sonal data that has been processed about him or her,
including individual results of research. At the same time
also the right not to know is preserved [3]. In many HBM
studies individual results are often not provided to the
research subjects based on one of the following argu-
ments: (1) the lack of relevance of the results at individual
level; (2) too limited time and/or resources; and (3) fear
of causing (unnecessary) alarm; (4) scientific uncertainty;
(5) lack of potential for remediation. In fact, the currently
used biomarkers may be measured without the possibility
for implicit information to the research subjects, to the
general public or to other authorities on the potential
health consequences or on measures for policy develop-
ment and prevention. Although individual results are
often not communicated since they may not (yet) be
meaningful at individual level, the research subjects have
a legal right to know their individual results of research.
Furthermore, the question emerges what to do in case of
conflict between the right not to know and the duty to
inform? During research, results at individual level can be
found that need preventive or curative action. However,
prior to the commencement of research, the wish of the
participant to know or not to know has to be established.
Although research situated in the public health context is
generally carried out without presumed direct benefits for
the individual, how can be guaranteed that the relevant
individual receives appropriate preventive action or ther-
apy?Environmental Health 2008, 7(Suppl 1):S7 http://www.ehjournal.net/content/7/S1/S7
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Methodology for critical analysis of ethico-legal 
contexts of HBM practices
The need for 'rethinking' the current ethical framework is
studied using a methodology for assessment of consist-
ency in respect to ethical values generally considered as
part of EU socio-ethical discourse. This methodology has
been developed in the context of three earlier European
projects [8-11]. Application of biomonitoring in the
workplace analyzed with the same method has led to the
development of appropriate rules to give guidance on
how ethical and responsible HBM is consequently under-
taken. It is expected that these lessons learned might be
supportive to HBM practices in the area of public health.
Four successive steps can be distinguished: (1) identifica-
tion of the global socio-economical and political context,
(2) analysis of the de facto practices, (3) analysis of the
national decision making process and (4) evaluation
against European standard values highlighting respect for
human dignity, social justice, solidarity and democratic
participation.
A bottom up approach is adopted, meaning that continu-
ous investigation and analysis of current research practices
is performed, starting with the information collected from
formal and informal contacts, interviews, questionnaires
etc. Paradigm cases are selected and virtual case scenarios
developed which will constitute a template for systematic
discussion on the issues of concern with all involved par-
ties. The virtual case scenarios start from real cases, with
additional 'elements' that facilitate focusing on these
issues. This approach not only allows collecting precise
information on real life complexity and obstacles, but
also inspires the development of solutions towards a con-
sistent ethical approach together with all involved parties.
With the methodology -that was proven efficient in previ-
ous research- serving as a solid backbone, the reflection on
the paradigm cases and other (virtual) case scenarios, con-
ducted in an open atmosphere by diverse stakeholders,
creates the opportunity to assess not only whether there is
a justified need for rethinking the ethical framework for
environmental health research, but also to identify possi-
ble solutions. The method also offers insight into differ-
ences in practices and in perception on the issues at stake
in different Member States and into the rationale for these
differences. Consequently, the analytical comparison of
practices taking into account specific (national) contexts
may lead to the identification of levers for a harmonized
approach in terms of respect of well-defined common val-
ues, but without necessarily making the practices identi-
cal.
An intermediate problem solving approach
Working with different research teams in the EU funded
projects ECNIS and NewGeneris learned that the focus of
activities with respect to ethical analysis had to be wid-
ened to fulfill also more immediate and practical needs.
The challenge consists of elaborating very concrete and
clear practical guidelines and solutions that not only guar-
antee the respect of ethical values, but at the same time
reduce the perceived burden of ethical constraints, both
for the research subjects and the researchers.
From the cases collected, it became apparent that due to
the specific public health context, there is a need for
appropriate communication strategies, at recruitment,
during and also at the end of a project. Appropriate com-
munication strategies are being developed for biomarkers
of exposure, effects, risk and susceptibility. For each cate-
gory of biomarkers possible ethical pitfalls are identified.
In the labyrinth of rules and guidelines, a proposal for
solution regarding secondary use, transfer of data and the
need for ethical approvals and notification in transna-
tional research consists out of two levels: proposals for
facilitation of international research in the context of envi-
ronmental and public health are being developed and
tested at the project level and will later on result in a pro-
posal at European level. The proposal at project level
encloses in the first place a very practical roadmap show-
ing how to comply with legislation, and is then followed
by a proposal for facilitation, representing possible situa-
tions the researcher might find himself in with corre-
sponding legal requirements.
Conclusion
Current and future research activities using human
biomarkers are facing new challenges and expectancies on
sensitive socio-ethical issues. Profound rethinking of the
current ethical and legal framework, issuing from clinical
medicine, putting emphasis on decisional autonomy, is
desired since it does not seem to give appropriate guid-
ance when the notion of public health moves to the fore-
front. Specific bottlenecks relate, amongst others, to
communication of results – which are often open for
interpretation – at individual, as well as at collective level,
translation into policy, and secondary use of material in
transnational research. The need for research on legal,
socio-ethical and communication aspects of HBM to
tackle these bottlenecks is fully recognized and being car-
ried out within the scope of several EU funded projects,
such as ECNIS NoE and NewGeneris IP, striving to con-
tribute to solutions in which the human rights and dignity
of research subjects are protected, whilst simultaneously
promoting development and use of human biomarkers.
Research is performed by a bottom-up approach, based
on a methodology for comparative analysis of determi-
nants in ethical reasoning, allowing to take into account
different social, cultural, political and historical tradi-
tions, in view of safeguarding common EU values. Based
on the information collected in the field, paradigm casesPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Environmental Health 2008, 7(Suppl 1):S7 http://www.ehjournal.net/content/7/S1/S7
Page 7 of 7
(page number not for citation purposes)
and virtual case scenarios are developed. These are dis-
cussed considering relevant stakeholders in order to
openly discuss possible obstacles and to identify options
for improvement in regulations.
A harmonized socio-ethical and legal approach, including
procedures for effective and appropriate communication,
not only increases the possibilities for comparison
between data generated but may also allow for improved
equality in the protection of the rights of citizens of
Europe and to establish trustful relationships between sci-
ence and society, based on firmly rooted ethical values in
EU legislative framework, which is crucial for further
developments within the public and academic research-
ers.
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